Reported about 15 hours ago
Jim Cramer's favorite stock, AbbVie Inc. (NYSE:ABBV), has seen a rise following the completion of important studies on its drugs, ABBV-101 and Budigalimab, which focus on food interactions and HIV treatment, respectively. Bank of America has also upgraded its price target for the stock from $220 to $251. With AbbVie showing promising monthly gains and strong hedge fund interest, it reinforces its reputation as a solid investment despite the competitive landscape.
Source: YAHOO